Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Supernus Pharmaceuticals Inc shares valued at $3,029,336 were sold by Khattar Jack A. on Oct 09 ’25. At $50.57 per share, Khattar Jack A. sold 59,900 shares. The insider’s holdings dropped to 1,206,578 shares worth approximately $67.18 million following the completion of this transaction.
Also, NEWHALL CHARLES W III sold 25,000 shares, netting a total of over 1,269,234 in proceeds. Following the sale of shares at $50.77 each, the insider now holds 104,644 shares.
Before that, JACK A. KHATTAR had added 59,900 shares to its account. In a trade valued at $2,875,200, the Director bought Supernus Pharmaceuticals Inc shares for $48.00 each.
As published in a research note from Piper Sandler on October 09, 2025, Supernus Pharmaceuticals Inc [SUPN] has been rated up from a Neutral to an Overweight and the price target has been revised to $65. Analysts at Cantor Fitzgerald upgraded the stock from ‘”a Neutral”‘ to ‘”an Overweight”‘ outlook in a report released in late July. As of February 19, 2025, Cantor Fitzgerald has decreased its “an Overweight” rating to a “Neutral” for SUPN. Earlier on January 06, 2025, Cantor Fitzgerald initiated its rating. Their recommendation was “an Overweight” for SUPN stock.
Analyzing SUPN Stock Performance
On last trading session, Supernus Pharmaceuticals Inc [NASDAQ: SUPN] rose 4.72% to $55.68. The stock’s lowest price that day was $53.18, but it reached a high of $55.945 in the same session. During the last five days, there has been a surge of approximately 9.89%. Over the course of the year, Supernus Pharmaceuticals Inc shares have jumped approximately 64.10%. Shares of the company reached a 52-week high of $55.94 on 10/29/25 and a 52-week low of $29.16 on 05/07/25.
Support And Resistance Levels for Supernus Pharmaceuticals Inc (SUPN)
According to the 24-hour chart, there is a support level at 53.91, which, if violated, would cause prices to drop to 52.14. In the upper region, resistance lies at 56.70. The next price resistance is at 57.71. RSI (Relative Strength Index) is 82.42 on the 14-day chart, showing overbought technical sentiment.
Is Supernus Pharmaceuticals Inc subject to short interest?
Stocks of Supernus Pharmaceuticals Inc saw a sharp steep in short interest on 2025-10-15 dropping by 65044.0 shares to 4.95 million. Data from Yahoo Finance shows that the short interest on 2025-09-15 was 5.02 million shares. A decline of -1.31% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.35 of the overall float, the days-to-cover ratio (short ratio) decline to 6.35.
Which companies own the most shares of Supernus Pharmaceuticals Inc (SUPN)?
In terms of Supernus Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 64 in the next 12 months, up nearly 20.37% from the previous closing price of $53.17. Analysts anticipate Supernus Pharmaceuticals Inc stock to reach 65 by 2025, with the lowest price target being 63. In spite of this, 3 analysts ranked Supernus Pharmaceuticals Inc stock as Buy at the end of 2025. On September 11, 2024, Piper Sandler assigned a price target of “a Neutral” to the stock and downgraded coverage with a $36.
